BP-1002 is under clinical development by Bio-Path and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to GlobalData, Phase I drugs for Relapsed Acute Myeloid Leukemia have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BP-1002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

BP-1002 overview

BP-1002 is under development for the treatment of refractory/relapsed follicular lymphoma and other forms of Non-Hodgkin’s lymphoma including diffuse large B-cell lymphoma, Waldenstrom macroglobulinemia, peripheral t-cell lymphomas, cutaneous t-cell lymphoma, extranodal marginal zone B-cell lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma), mantle cell lymphoma, chronic lymphocytic leukemia (CLL),  Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), refractory and relapsed acute myeloid leukemia (AML). It is administered as an intravenous infusion. The therapeutic candidate acts by targeting B cell lymphoma 2 (Bcl 2). It is developed based on DNAbilize, neutral lipid delivery technology which uses positively charged lipids to form complexes between the lipids and the molecules allowing high concentration of the drug to be delivered to the diseased cells. It was also under development for the treatment of Burkitt lymphoma.

Bio-Path overview

Bio-Path is a clinical stage biotechnology company that develops targeted therapies for acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and other challenging cancers. The company provides products pipeline such as prexigebersen and BP1002 (Liposomal Bcl2). Its prexigebersen, is developed for the treatment of Acute Myeloid Leukemia (AML) and solid tumors. Bio-Path’s BP1002 (Liposomal Bcl2) is used for the treatment of lymphoma, leukemia, colon, prostate and breast cancers, among others. The company’s proprietary liposomal delivery and antisense technology platform DNAbilize, is used to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Bio-Path is headquartered in Bellaire, Texas, the US.

For a complete picture of BP-1002’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.